Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer
Rajendra Karki, Bhesh Raj Sharma, Ein Lee, Balaji Banoth, R.K. Subbarao Malireddi, Parimal Samir, Shraddha Tuladhar, Harisankeerth Mummareddy, Amanda R. Burton, Peter Vogel, Thirumala-Devi Kanneganti
Rajendra Karki, Bhesh Raj Sharma, Ein Lee, Balaji Banoth, R.K. Subbarao Malireddi, Parimal Samir, Shraddha Tuladhar, Harisankeerth Mummareddy, Amanda R. Burton, Peter Vogel, Thirumala-Devi Kanneganti
View: Text | PDF
Research Article Immunology Oncology

Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer

  • Text
  • PDF
Abstract

Interferon regulatory factor 1 (IRF1) regulates diverse biological functions, including modulation of cellular responses involved in tumorigenesis. Genetic mutations and altered IRF1 function are associated with several cancers. Although the function of IRF1 in the immunobiology of cancer is emerging, IRF1-specific mechanisms regulating tumorigenesis and tissue homeostasis in vivo are not clear. Here, we found that mice lacking IRF1 were hypersusceptible to colorectal tumorigenesis. IRF1 functions in both the myeloid and epithelial compartments to confer protection against AOM/DSS-induced colorectal tumorigenesis. We further found that IRF1 also prevents tumorigenesis in a spontaneous mouse model of colorectal cancer. The attenuated cell death in the colons of Irf1–/– mice was due to defective pyroptosis, apoptosis, and necroptosis (PANoptosis). IRF1 does not regulate inflammation and the inflammasome in the colon. Overall, our study identified IRF1 as an upstream regulator of PANoptosis to induce cell death during colitis-associated tumorigenesis.

Authors

Rajendra Karki, Bhesh Raj Sharma, Ein Lee, Balaji Banoth, R.K. Subbarao Malireddi, Parimal Samir, Shraddha Tuladhar, Harisankeerth Mummareddy, Amanda R. Burton, Peter Vogel, Thirumala-Devi Kanneganti

×

Figure 2

IRF1 functions in both the myeloid and epithelial cell to prevent colitis-associated colorectal tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
IRF1 functions in both the myeloid and epithelial cell to prevent coliti...
(A) Representative images of colon tumors in WT, LysMCreIrf1fl/fl, VillinCreIrf1fl/fl, and Irf1–/– mice 80 days after azoxymethane (AOM) injection. (B) Number of colon tumors in WT (n = 10), LysMCreIrf1fl/fl (n = 10), VillinCreIrf1fl/fl (n = 10), and Irf1–/– (n = 7) mice. (C) Percentage of tumors of various sizes in WT, LysMCreIrf1fl/fl, VillinCreIrf1fl/fl, and Irf1–/– mice 80 days after AOM injection. (D) Body weight change in WT, LysMCreIrf1fl/fl, VillinCreIrf1fl/fl, and Irf1–/– mice 80 days after AOM injection. Each symbol represents 1 individual mouse in B. *P < 0.01; ****P < 0.0001. One-way ANOVA (B) was used. Data are representative of 2 independent experiments. Data are represented as mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts